← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Blood Cell Technologies, Llc
Stony Brook, NY
$3,489,763
Total funding
6
Grants
Funding over time
peak $898.4K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,489,763 · 6
By mechanism
R44$2,468,166 · 2
R43$1,021,597 · 4
Investigators at Blood Cell Technologies, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production$763,993
R44 · FY2022 · HL
Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production$690,965
R44 · FY2021 · HL
Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production$613,208
R44 · FY2023 · HL
Development of Second Generation BLVRB Inhibitors for Treating Chemotherapy Induced Thrombocytopenia$400,000
R44 · FY2025 · CA
Development of a new class of BLVRB-targeted redox therapeutics in breast cancer$285,200
R43 · FY2023 · CA
Detection of fetal platelets in maternal blood using platelet RNA biomarkers.$272,302
R43 · FY2020 · HL
HLS-Detection of RNA biomarkers in individual platelets$243,104
R43 · FY2017 · AG
Development of a biliverdin IX Beta reductase redox inhibitor for enhanced platelet production$220,991
R43 · FY2015 · HL